Hirashima Takafumi, Chihara Tomoyuki, Bun Toshitaka, Utsumi Takao, Hirose Miou, Oh Hideyasu
Department of Ophthalmology, Hyogo Prefectural Amagasaki Hospital, 1-1-1 Higashi-daimotsu-cho, Amagasaki, Hyogo 660-0828, Japan.
J Ophthalmol. 2014;2014:173084. doi: 10.1155/2014/173084. Epub 2014 Jul 7.
Background. To evaluate the efficacy of intravitreal bevacizumab (IVB) injection with or without macular laser photocoagulation (MLP) for recurrent or persistent macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods. Thirty-four eyes underwent IVB injection for ME secondary to BRVO as a primary treatment. Twenty of the 34 eyes experienced recurrent or persistent ME after the first IVB. Nine of the 20 eyes (Group 1) were retreated with IVB combined with MLP. The remaining 11 eyes (Group 2) were retreated with IVB alone. Results. In Group 1, the postoperative best corrected visual acuity (BCVA) improved compared with the preoperative value at all follow-up visits, although no statistically significant improvement was observed at 6 months. In contrast, BCVA significantly improved from 0.53 to 0.40 at 6 months (P < 0.05) in Group 2. Conclusion. Combined therapy tended to have a smaller effect on visual acuity compared with IVB monotherapy.
背景。评估玻璃体内注射贝伐单抗(IVB)联合或不联合黄斑激光光凝(MLP)治疗视网膜分支静脉阻塞(BRVO)继发的复发性或持续性黄斑水肿(ME)的疗效。方法。34只眼接受IVB注射作为原发性治疗BRVO继发的ME。34只眼中有20只眼在首次IVB后出现复发性或持续性ME。20只眼中的9只眼(第1组)接受IVB联合MLP再次治疗。其余11只眼(第2组)仅接受IVB再次治疗。结果。在第1组中,所有随访时术后最佳矫正视力(BCVA)均较术前有所改善,尽管在6个月时未观察到统计学上的显著改善。相比之下,第2组在6个月时BCVA从0.53显著提高到0.40(P < 0.05)。结论。与IVB单药治疗相比,联合治疗对视力的影响往往较小。